Philadelphia chromosome in essential thrombocythemia?

Essential thrombocythemia

Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000. The median age at diagnosis is 65 to 70 years, but the disease may occur at any age. The female to male ratio is about 2:1. The clinical pictu...

Thrombospondin in essential thrombocythemia.

Essential thrombocythemia is a myeloproliferative disorder characterized by frequent bleeding and thrombotic complications. On a molecular level, two abnormalities of platelet thrombospondin have been identified: abnormal glycosylation of the intact 185,000-dalton chain has been detected and a shortened form of the thrombospondin chain is present. We have used two monoclonal antibodies and Lens...

BCR-ABL Transcripts in Bone Marrow Aspirates of Philadelphia-Negative Essential Thrombocythemia Patients: Clinical Presentation

One of the diagnostic criteria of essential thrombocythemia laboratory characteristics, except for a significant increased patients’ age and decreased polymorphonuclear cell count (ET) is the absence of the Philadelphia chromosome (Phneg). On the molecular level, Ph-neg ET patients may carry in the BCR-ABL positive group. During a median follow-up of 20 and 22.5 months for the BCR-ABL negative ...

Ruxolitinib for essential thrombocythemia?

Thromboembolic complication in Essential Thrombocythemia

Pan African Medical Journal. 2012; 13:58 This article is available online at: http://www.panafrican-med-journal.com/content/article/13/58/full/ © Zahra Mozaheb et al. The Pan African Medical Journal ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, d...